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Complement (C5b-9) induces glomerular epithelial cell DNA
synthesis but not proliferation in vitro
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Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington, USA
Complement (C5b-9) induces glomerular epithelial cell DNA Complement is a critical mediator of antibody-induced
synthesis but not proliferation in vitro. renal disease [1]. Established effects include generation
Background. The C5b-9 membrane attack complex of com- of chemotactic factors such as C5a leading to recruitment
plement is the principal mediator of injury induced experimen- of circulating inflammatory cells and formation of thetally by antibodies directed at glomerular cell membranes. In
C5b-9 membrane attack complex of complement whichexperimental membranous nephropathy, C5b-9 induced injury
can insert into and activate renal cells to make otherto the glomerular visceral epithelial cell (VEC) is associated
with DNA synthesis, but not cytokinesis. In the current study inflammatory mediators [2, 3]. The role of C5b-9 has
we determined if C5b-9 increases DNA synthesis in VEC in been best established in renal diseases induced experi-
vitro, and defined the mechanisms involved. mentally by antibodies to glomerular cell membrane an-
Methods. Rat VEC in vitro were divided into three groups: tigens. Thus, C5b-9 is the principal mediator of injury
(1) sensitized with anti-VEC antibody and exposed to sublytic
induced by antibody to the glomerular visceral epithelialconcentrations of C 1/PVG serum (normal complement com-
cell (VEC) (passive Heymann nephritis; PHN) [4–7],ponents); (2) anti-VEC antibody and control C-/PVG serum
mesangial cell (experimental mesangial proliferative glo-(C6 deficient); (3) no anti-VEC antibody. DNA synthesis
(BrdU staining), mitosis (mitotic figures) and cytokinesis (cell merulonephritis, Thy1 model) [8], and endothelial cell
counts) were measured at 24 and 48 hours. To examine the (thrombotic microangiopathy model) [9].
expression of specific S-phase and M-phase cell cycle regulatory Of note, however, is that the consequences of C5b-9
proteins and their inhibitors, immunostaining and Western blot attack appear to differ depending on which cell type is
analysis was performed for cyclin A, CDK2, p21 and p27, cyclin
involved. In the mesangium, antibody and complementB and cdc2.
induce mesangial cell lysis, followed by a phase of prolif-Results. In the absence of growth factors, sublytic C5b-9
eration [8, 10]. In contrast, C5b-9 attack on the VEC inattack did not increase proliferation. In contrast, sublytic C5b-9
attack (group 1) augmented growth factor induced DNA syn- vivo does not cause lysis and is followed by cell activation
thesis by 50% compared to controls (groups 2 and 3; P , and DNA synthesis, occasional mitosis and ploidy [11–
0.001), and was accompanied by increased levels of cyclin A 13]. However, the VEC does not readily undergo cytoki-
and CDK2, and a decrease in the cyclin kinase inhibitor p27 nesis (cell division) and the VEC number does not in-(but not p21). Sublytic C5b-9 attack reduced the expression of
crease in vivo [14]. It is likely that this failure of thethe M phase cell cycle proteins, cyclin B and cdc2, accompanied
VEC to proliferate in some forms of glomerular diseaseby reduced mitosis (mitotic figures) and cytokinesis (cell
contributes to glomerular sclerosis and renal failurenumber).
Conclusions. Our results show that the C5b-9 augmented [15–17].
growth factor entry into the S phase in VEC is regulated by Cell proliferation is ultimately controlled in the nu-
changes in specific cell cycle regulatory proteins. However, cleus at the level of the cell cycle, and requires a transi-
antibody and complement decreased the M phase cell cycle
tion through specific phases of the cell cycle [18]. Eachproteins, and prevented VEC mitosis and cytokinesis, sug-
phase of the cell cycle serves a unique role in preparinggesting a delay or arrest at the G2/M phase.
a cell to proliferate (increase in cell number) [19]. Thus,
the S phase is required for DNA synthesis, and the M
phase is required for mitosis and cell division (cytokine-Key words: p27, cyclins, cell cycle, proliferation, podocyte, membrane
attack complex, visceral epithelial cell. sis) [20]. Each phase of the cell cycle is governed by
specific positive cell cycle regulatory proteins calledReceived for publication July 31, 1998
cyclins and cyclin dependent kinases (CDK) [21]. DNAand in revised form February 5, 1999
Accepted for publication March 8, 1999 synthesis (S phase) requires that CDK2 be activated
by its partner cyclin A [22]. Mitosis and cytokinesis 1999 by the International Society of Nephrology
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(M phase) require that cdc2 (formerly called CDK1) three times, and the cells were then incubated in serum-
free media or media with serum.be activated by cyclin B [23]. In contrast, cyclin kinase
Group 2. VEC served as a control for C5b-9 attackedinhibitors such as p21 and p27 inhibit cell cycle progres-
cells. VEC were sensitized with anti-Fx1A IgG and thension by inactivating specific cyclin-CDK complexes [24].
exposed to serum for 60 minutes that lacked C6 (PVGTo better understand the consequences of C5b-9 in-
C2 serum, see below), washed, and incubated in serumduced injury in diseases of the VEC, we have examined
free media or media with serum.the effects of sublytic C5b-9 attack on VEC proliferation
Group 3. VEC served as a control for anti-Fx1A IgG:by examining DNA synthesis, mitosis and cytokinesis in
VEC were exposed to media at 378C for 30 minutes invitro as they relate to changes in expression of cell cycle
the absence of anti-Fx1A.regulatory proteins. To our knowledge, our results pro-
vide the first evidence that C5b-9 increases DNA synthe-
sis in a resident glomerular cell, suggest that this effect Experimental design
is mediated in part by additional cell-derived mitogen(s), Two experimental conditions were used to answer spe-
and establish a role for cell cycle regulatory proteins cific questions. To determine if sublytic C5b-9 attack
in the response of the VEC to complement-mediated was sufficient to increase DNA synthesis, mitosis and
injury. cytokinesis in the absence of a source of growth factors
(Nuserum), VEC from each group were incubated in
serum free media for 18 to 48 hours. To determine ifMETHODS
sublytic C5b-9 attack augmented DNA synthesis and
Glomerular epithelial cell culture and mitosis induced by growth factors, VEC from each group
experimental design where grown in Nuserum for 18 to 48 hours.
Rat visceral glomerular epithelial cells (VEC) (podo-
Preparing sublytic C5b-9 attackcytes) were established in culture as previously described
[25]. In brief, glomeruli were isolated from 60 to 100 g Serum from normocomplementemic PVG rats (C1;
male Sprague-Dawley rats (Simonsen, Gilroy, CA, Harlan Sprague-Dawley, Indianapolis, IN, USA) was
utilized as a complement source to induce sublytic C5b-9USA) by differential sieving, and placed in culture dishes
attack. Serum from C6 deficient-PVG rats (C2; Bantincontaining Vitrogen (Celtrix, Santa Clara, CA, USA)
and Kingman Universal, Edmonds, WA, USA) was usedand K-1 Media consisting of Ham’s F-12 and DME-low
as control. C2 rats exhibit a complete absence of C6,glucose 1:1 (Gibco, Grand Island, NY, USA) with 2%
inherited in an autosomal recessive pattern, and areNuSerum (Collaborative Biomedical Products, Bedford,
therefore unable to assemble C5b-9 [27]. Serum wasMA, USA) and ITS Premix (Collaborative Biomedical
obtained from both rat strains by aortic puncture andProducts). After five to seven days, colonies of VEC
allowed to clot. The serum was separated by centrifuga-were marked in the culture dish, excised, and replated.
tion, sterile filtered on ice and stored at 2708C. TheInitially, cells were passaged every four to five days onto
serum was tested in a CH50 hemolytic assay to establishvitrogen and after 20 passages they were passaged onto
the complement activity [28]. C1 serum exhibited com-plastic. VEC were characterized by established criteria,
plement activity equivalent to normal Sprague-Dawleywhich included a polygonal shape and cobblestone ap-
rat serum. C2 serum had no hemolytic activity. In selectpearance at confluency, and positive staining with anti-
experiments, serum from Sprague-Dawley rats was alsobodies to Fx1A, cytokeratin, and podocalyxin and
used as a source of complement, and heat-inactivatednegative staining with antibodies directed against the
Sprague-Dawley rat serum was used as a control.mesangial cell (Thy-1) and endothelial cell (Factor VIII)
The selection of the antibody and complement concen-[25].
trations used in the current study was based on checker-
board titration studies to define the maximal amountsAntibody-C5b-9 stimulation of VEC
of antibody and complement that could be used without
To induce sublytic C5b-9 attack, VEC were split 1:3, producing VEC injury or lysis (defined as .5% LDH
plated overnight in K-1 media, and allowed to grow to release; see below). Serum was diluted to 4% in serum
50% confluency. VEC were washed three times with free K-1 media and applied to the antibody sensitized
serum-free K-1 media, and divided into three groups. VEC for one hour at 378C to allow C5b-9 insertion. VEC
Group 1. VEC were sensitized with 3 mg/ml of sheep- were then washed with serum free K-1 media to remove
anti-Fx1A IgG at 378C for 30 minutes [26]. Unbound any unbound complement.
antibody was removed by washing three times with se-
Lactate dehydrogenase assayrum free K-1 media. Sensitized VEC were then exposed
to a sublytic complement source (PVG C1 serum, see To ensure that C5b-9 attack was not inducing signifi-
cant cell lysis, lactate dehydrogenase (LDH) was mea-below) in the media for 60 minutes. VEC were washed
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sured in the supernatants using the Lactate Dehydroge- ber of mitotic figures/HPF were counted in 20 fields, and
were expressed as a percentage of the total cell count.nase Kinetic Assay Kit (Sigma Diagnostics, St. Louis,
To determine if C5b-9 increased cell division (cytoki-MO, USA) [29]. Conditioned media was removed one
nesis), the cell number was measured prior to exposurehour after the addition of the complement source, and
to anti-Fx1A antibody, and at 24 and 48 hours in groupthe remaining cells were lyzed with 2% triton. The condi-
1 and group 2 VEC grown in Nuserum. Cell number wastioned media or the lyzed cells were diluted 1:60 in nico-
reported as the percentage increase from the start of thetinamide adenine dinucleotide reduced form (NADH)
experiment at each of these time points.1 mg/ml. Sodium pyruvate solution was then added, and
the reduction of NADH to NAD by the LDH in the
Determining if mitogens are released followingmedia or the lyzed cells was measured by a drop in
sublytic C5b-9 attackabsorbance at 340 nm by a Lambda Bio Spectrophotom-
To determine if sublytic C5b-9 attack was associatedeter (Perkin Elmer, Norwalk, CT, USA). Lysis was ex-
with the release of mitogens, group 1 and 2 VEC werepressed as a percentage of the change in the absorbance
incubated in Nuserum-free media for 18 hours after ex-of the media compared to changes in absorbance of the
posure to anti-Fx1A antibody and C1 serum or C2triton lyzed cells and the media. Less than 5% LDH
serum. The supernatants were collected after 18 hours,release was regarded as sublytic.
and transferred to VEC that were growing at 50% con-
fluency in Nuserum-containing media, and BrdU immu-S phase measured by BrdU staining
nostaining was measured in these cells after 18 hours.To determine if attack by antibody and C5b-9 was
sufficient to augment DNA synthesis in VEC grown in Basic fibroblast growth factor and TGF-b1
the absence of growth factors, VEC from groups 1, 2 blocking studies
and 3 were incubated in Nuserum-free media for 18
To test the hypothesis that C5b-9-induced DNA syn-hours. To determine if sublytic C5b-9 attack augmented
thesis resulted in part from the release of mitogenicDNA synthesis induced by growth factors, VEC from
growth factors, a neutralizing antibody to basic fibroblasteach group were incubated in media containing serum
growth factor (bFGF) was used to block bFGF activityand other growth factors (2% Nu serum) for 18 hours
following complement stimulation. Goat anti-bFGF (ob-after the C5b-9 attack. Comparisons were made to group
tained from Dr. Michael A. Reidy, Dept. of Pathology,2 and group 3 VEC grown in 2% Nu serum for 18 hours.
University of Washington, Seattle, WA, USA) or controlIn each experiment, entry to the S phase was measured
goat IgG was added at 1 mg/ml to the K-1 media follow-
by BrdU immunostaining, a marker of DNA synthesis.
ing the addition of a complement source. VEC were
BrdU staining (5-bromo-29-deoxyuridine) was measured incubated with anti-bFGF antibody for 18 hours, and
with a cell proliferation kit (Amersham Life Science, DNA synthesis was measured. To ensure that the con-
Arlington, IL, USA) as previously described [30]. In centration of anti-bFGF used in this study inhibited
brief, VEC were pulsed with BrdU (1:500 dilution) in bFGF, additional experiments were performed where
media with or without Nuserum for 18 hours, and immu- recombinant bFGF (10 ng/ml) was added to quiescent
nostaining was performed according to the manufactur- VEC in the presence of anti-bFGF or control goat IgG.
er’s directions. BrdU was detected using a monoclonal Because transforming growth factor-b1 (TGF-b1) has
antibody to BrdU, followed by a peroxidase conjugated been shown to reduce growth factor-induced prolifera-
sheep-antimouse IgG2a antibody and Diaminobenzidine tion in many cell types including VEC [31], the effect of
with cobalt and nickel. Camco quick stain II (Baxter TGF-b1 on C5b-9 stimulated DNA synthesis was also
Scientific Products, McGaw Park, IL, USA) was used as assessed. TGF-b1 (10 ng/ml; R&D Systems, Minneapo-
a nuclear counterstain. To determine the percentage of lis, MN, USA) was activated in 4 mm HCl containing
cells staining positive for BrdU, 200 VEC were counted, 0.1% BSA and added to VEC at a concentration of 10
and the percentage of VEC staining positive for BrdU ng/ml following exposure to C5b-9. DNA synthesis was
was determined. All the experiments reported in this measured 18 hours later.
study were performed a minimum of six times.
Determining the expression of cell-cycle regulatory
Measuring the M phase of the cell cycle proteins in VEC
Cell proliferation requires that a cell complete both The levels of S phase and M phase cell-cycle regulatory
the S phase and M phase of the cell cycle. To determine proteins were determined by immunostaining and West-
if C5b-9 increased entry into the M phase, mitotic figures ern blot analysis [10, 30] in group I (C5b-9 attack) and
[23], a marker of the M phase, were counted in group 1 2 (control) cells after 18 hours of exposure to Nuserum.
(sublytic C5b-9 attack) and group 2 (anti-Fx1A without Immunostaining. VEC were grown on 24-well plates,
and fixed in 1:1 methanol/acetone for 15 minutes atC5b-9) VEC grown in Nuserum for 24 hours. The num-
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2208C, then washed three times in cold PBS. The cells sis included omitting the primary antibody, replacing the
primary antibody with an irrelevant antibody of the samewere permeabilized with 0.5% NP-40 buffer for 10 min-
utes at room temperature. Following a wash in PBS, species and peptide absorption (the source of peptides
was the same as the primary antibody).primary affinity purified rabbit polyclonal antibodies [10,
30] to cyclin A (dilution 1:1000; provided by J.M. Rob-
Statisticserts, Fred Hutchinson Cancer Research Center, Seattle,
WA, USA), CDK2 (dilution 1:1000; Santa Cruz Biotech- Values were reported as mean 6 sem, unless otherwise
stated. Statistical significance (P , 0.05) was evaluatednology, Santa Cruz, CA), cyclin B1 (dilution 1:100; Santa
Cruz Biotechnology) cdc2 (dilution 1:100; Santa Cruz using the Student’s t-test, and a modified t-test was per-
formed using the Bonferroni-Dunn correction.Biotechnology), p21 (dilution 1:1000; Santa Cruz Bio-
technology) and p27 (dilution 1:1000; provided by J.M.
Roberts), were incubated overnight at 48C. A secondary
RESULTS
biotinylated goat antirabbit antibody was added (1:400
C5b-9 augments growth factor-induced DNA synthesisdilution, Vector Laboratories) for 60 minutes at room
in VEC in vitrotemperature, followed by streptavidin FITC (1:32 dilu-
tion; Cappel Research Products, Durham, NC, USA) or Entry into the S phase of the cell cycle was measured
by BrdU staining, a marker of DNA synthesis. A firstAvidin D horseradish peroxidase (1:2000) for 60 minutes
at room temperature, followed by 49, 6-diamidino-2- question was to determine if sublytic C5b-9 attack in-
creased DNA synthesis in the absence of growth factorsphenylindole (Boehringer Mannheim, Indianapolis, IN,
USA). Nuclei were counterstained with Camco Quick (in this study Nuserum was used as a source of growth
factors). Accordingly, BrdU staining was quantitated inStain II (Baxter Scientific Products). The number of
VEC staining positive for each cell cycle protein was each VEC group grown in Nuserum-free media for 18
hours, and the results are shown in Table 1. In the ab-expressed as a percentage of the total number of cells.
Western blot analysis. Cell protein was obtained from sence of a source of growth factors (Nuserum-free me-
dia) there was no difference in BrdU staining in eachgroup 1 (C5b-9 attacked) and group 2 (control) VEC
after an 18 hour exposure to Nuserum. At each time group. Thus, the sublytic C5b-9 attack alone did not
increase DNA synthesis.point VEC were washed three times with cold PBS,
trypsinized, and following centrifugation, the pellet was A second question asked if the sublytic C5b-9 attack
augmented DNA synthesis induced by growth factors.resuspended in a buffer containing 1% triton, 10% glyc-
erol, 20 mm HEPES, 100 mm NaCl with 10 mg/ml leupep- Table 1 shows there was an increase in BrdU staining
in group 2 (anti-Fx1A without C5b-9) and group 3 (notin, 10 mg/ml antipain, 10 mg/ml pepstatin, 0.1 mm sodium
orthovanadate and 50 mm sodium fluoride (reagents pur- anti-Fx1A antibody) VEC in the presence of serum com-
pared to Nuserum-free conditions. There was no differ-chased from Sigma Biosciences). Following a vortex, the
VEC were placed on ice for 15 minutes, centrifuged at ence in BrdU staining in group 2 and 3 VEC at 18 hours.
In contrast, there was approximately a twofold increase14,000 r.p.m. for 5 minutes, and the protein concentration
of the supernatant was measured by a BCA protein assay in BrdU staining in group 1 (sublytic C5b-9 attack) VEC
compared to control (group 2 and group 3) VEC.(Pierce, Rockford, IL, USA). For Western blot analysis,
20 mg of VEC protein extract was loaded in each lane, In separate studies, sublytic C5b-9 attack induced with
Sprague-Dawley serum also increased BrdU stainingseparated under reducing conditions on a 15% SDS-
PAGE gel, and transferred to PVDF membranes (Milli- twofold compared to VEC exposed to antibody and heat-
inactivated Sprague-Dawley serum (P , 0.0001; data notpore, Bedford, MA, USA) by electroblotting. To reduce
nonspecific antibody binding, the membranes were first shown).
These results show that sublytic C5b-9 augmentedblocked with 5% nonfat dried milk for 30 minutes at
room temperature. This was followed by an overnight growth factor induced DNA synthesis in VEC in vitro,
and show that sublytic C5b-9 attack by itself was notincubation at 48C with antibodies to either cyclin A,
CDK2, p21, p27, cyclin B or cdc2. An alkaline phospha- sufficient to engage VEC into the S phase (DNA synthe-
sis) of the cell cycle in the absence of growth factors.tase-conjugated secondary antibody (Promega, Madison,
WI, USA) was used for detection with the chromagen,
VEC arrest at G2/M following C5b-9 attack5-Bromo-4-Chloro-3-Indolyl phosphate/nitro blue tetra-
zolium (Sigma Biosciences). The gels were stained with Entry into the M phase of the cell cycle was measured
by counting mitotic figures. Because DNA synthesis wasCoomassie Blue to check for complete protein transfer.
Following Western blot analysis, filters were also stained increased by C5b-9 only in the presence of serum, mitosis
was assessed at 24 hours following the sublytic C5b-9with Coomassie Blue to ensure that protein loading was
equal. attack in VEC grown in media with growth factors (Nu-
serum). There were 4.43 6 0.26 mitotic figures/HPF inControls for immunostaining and Western blot analy-
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Table 1. Quantitation of BrdU staining
Nuserum free (18h) Nuserum (18h)
Group Experiment % positive BrdU cells
1 Anti-Fx1A and C5b-9 1961.1 a,b6361.0
2 Anti-Fx1A and no C5b-9 18 61.0 a2762.8
3 No anti-Fx1A 1660.9 a30.363.8
a P , 0.001 vs. Nuserum free
b P , 0.001 vs. groups 2 and 3 Nuserum
Visceral epithelial cells (VEC) were divided into three groups based on the presence or absence of anti-VEC antibody and C5b-9, and were then grown in media
with or without Nuserum for 18 hours. Nuserum, a source of growth factors increased the percentage of cells that stained positive for BrdU, a marker of DNA
synthesis, was doubled by sublytic C5b-9.
Group 1 VEC, but the increase was less than 50% com-
pared to controls.
These results show that despite increased entry into
the S phase (DNA synthesis) at 18 hours induced by
C5b-9 attack, there was no corresponding increase in
entry into (mitosis) or progression through (cytokinesis)
the M phase of the cell cycle. Thus, sublytic C5b-9 attack
either causes VEC to arrest at the G2/M phase or delays
G2/M phase progression and entry into M phase, despite
the presence of growth factors (Nuserum) to which they
can respond.
C5b-9-induced VEC proliferation is induced in part by
a secreted mitogen
To determine if the increase in DNA synthesis (BrdU
staining) induced by C5b-9 and growth factors was due
to the release of mitogens from VEC, supernatants were
collected after 18 hours from each group of VEC and
transferred to normal VEC growing in Nuserum. DNA
Fig. 1. Quantitation of cell number. Glomerular visceral epithelial cells synthesis was measured by BrdU incorporation into
(VEC) were divided into three groups and cells were counted when
DNA at 18 hours after the transfer. When VEC wereplaced in media with Nuserum (0 hr) and at 24 and 48 hours. The cell
number was increased in control VEC [groups 2 (e) and 3 (s)] com- incubated with supernatants from control VEC (groups
pared to VEC exposed to sublytic C5b-9 (group 1; h) at 24 and 48 2 and 3), BrdU staining was not increased (19 6 1 vs.
hours. There was no difference in cell number in control VEC at 24
18 6 0.7, P . 0.05). In contrast, incubating VEC withand 48 hours. aP , 0.0010 vs. groups 2 and 3; bP , 0.0007 vs. groups
2 and 3; cP , 0.099 vs. group 3; dP , 0.24 vs. group 3. supernatants derived from VEC subjected to sublytic
C5b-9 attack (group 1) increased BrdU staining 1.5-fold
(28 6 0.1 vs. 18 6 0.7, P , 0.001).
Taken together, these results suggest that the increase
Group 2 (anti-Fx1A without C5b-9) VEC. In contrast, in DNA synthesis induced by C5b-9 attack was due in
there were only 0.52 6 0.73 mitotic figures/HPF in group part to mitogen(s) “released” following exposure of
1 (sublytic C5b-9 attack) VEC (P , 0.001 vs. group 2) VEC to sublytic C5b-9.
To determine the effect of sublytic C5b-9 on cytokine-
Complement-induced VEC DNA synthesis is not duesis (cell division), cell number was measured at 24 and
to bFGF48 hours following exposure to antibody with or without
a complement source in VEC grown in the presence of The cytokine bFGF is increased in experimental forms
Nuserum. Figure 1 shows that in control VEC (groups of VEC injury in vivo and bFGF is mitogenic for VEC
2 and 3) grown in Nuserum, there was a progressive [31, 32]. To determine if C5b-9 induced DNA synthesis
increase in cell number at 24 hours (P , 0.001 vs. 0 hr) was due to the release of bFGF from injured cells, DNA
and 48 hours (P , 0.001 vs. 24 hr). In contrast, cell synthesis was measured in the presence of a specific
number did not increase in VEC following sublytic C5b-9 neutralizing anti-bFGF antibody. Anti-bFGF antibody
attack (group 1) at 24 hours (P . 0.05 vs. groups 2 and did not reduce BrdU staining induced by C5b-9 stimula-
tion compared to control IgG (67 6 2.5 vs. 62 6 1.5%,3). However, cell number did increase at 48 hours in
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P . 0.05). The concentration of anti-bFGF antibody
used was effective as judged by a reduction in DNA
synthesis to baseline when bFGF was used as a mitogen
in the presence of antibody (results not shown). Taken
together, these results show that the increase in DNA
synthesis induced by C5b-9 was not due to bFGF.
Complement-induced VEC DNA synthesis is not
inhibited by TGF-b1
Because the cytokine TGF-b1 has been shown to in-
hibit specific mitogen-induced VEC proliferation in vitro
[31], we asked if TGF-b1 would inhibit complement-in-
duced VEC proliferation. The concentration of TGF-b1
used in the current study reduced BrdU staining signifi-
cantly in VEC exposed to growth factors to stimulate
mitogenesis (26.5 6 0.5 vs. 9 6 1, P , 0.05). In contrast,
DNA synthesis induced by sublytic C5b-9 was not re-
duced by TGF-b1 (52 6 1 vs. 49 6 0, P . 0.05).
C5b-9 increases cell cycle proteins required for
S phase
To better understand the effects of sublytic C5b-9 on
the VEC cell cycle, we measured the expression of the S
phase cyclin A and its partner CDK2 in Group 1 (sublytic
C5b-9 attack), and control group 2 (anti-Fx1A without
C5b-9) and group 3 (no anti-Fx1A) VEC at 18 hours,
the peak of DNA synthesis in this study when VEC were
grown in Nuserum-containing media. These cell cycle
regulatory proteins are required for DNA synthesis (S
phase) in other cell types [21], including mesangial cells
[30]. Less than 10% of control VEC stained positive for
CDK2 (results not shown). There was a marked increase
in the number of VEC staining positive for CDK2 in
Fig. 2. Western blot of S phase cell cycle regulatory proteins. Glomeru-C5b-9 attacked VEC (38%, P , 0.001 vs. controls; not
lar visceral epithelial cells (VEC) were sensitized to anti-Fx1A antibodyshown) at 18 hours. The increase in CDK2 protein levels and C5b-9 (group 1, lane 2), and grown in Nuserm-containing media
was confirmed by Western blot analysis (Fig. 2). for 18 hours with the antibody. Controls included VEC exposed to
antibody without C5b-9 (group 2, lane 3) or no antibody (group 3, laneFigure 2 shows that cyclin A was also detected in low
1). Cyclin dependent kinase-2 (CDK2) and cyclin A levels increasedlevels by Western blot analysis in control VEC (groups in VEC subjected to sublytic C5b-9 injury compared to controls, and
2 and 3) grown in Nuserum for 18 hours. There was also this coincided with the increase in DNA synthesis in these cells. C5b-9
caused a decrease in the levels of the cyclin kinase inhibitor p27, butan increase in cyclin A protein levels in C5b-9 attacked
did not alter p21 levels.VEC (group 1) compared to controls at 18 hours (Fig. 1).
These results demonstrate that expression of the S
phase cell cycle proteins, CDK2 and cyclin A is increased
in VEC exposed to sublytic C5b-9, data which demon-
by Western blot analysis (Fig. 2) in VEC exposed tostrate that these cells do exhibit the changes in cell cycle
sublytic C5b-9 compared to control in the presence ofproteins required to proliferate.
Nuserum.
In control VEC (groups 2 and 3) grown in Nuserum-C5b-9 causes a differential expression of cyclin
kinase inhibitors containing media where less than 20% of cells were un-
dergoing DNA synthesis, p27 protein was readily de-To further assess why DNA synthesis occurred in re-
tected by Western blot analysis (Fig. 2). In contrast, theresponse to C5b-9 but proliferation did not, the levels of
was a marked decrease in p27 levels in VEC followingthe cyclin kinase inhibitors (CKI), p21 and p27, were
exposure to sublytic C5b-9 (group 1) compared to con-measured by Western blot analysis. These CKI have
trols (groups 2), and this coincided with the increase inbeen shown to inhibit DNA synthesis by binding to cyclin
A-CDK2 complexes. There was no change in p21 levels DNA synthesis in these cells. These findings are also
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Fig. 3. Protein levels for cyclin B. The number of VEC staining positive for cyclin B (A) were higher in control VEC exposed to anti-Fx1A
antibody without C5b-9 (group 2) compared to VEC attacked by anti-Fx1A with C5b-9 (group 1) (B). Western blot analysis for cyclin B, confirming
a decrease in cyclin B levels in VEC exposed to sublytic C5b-9 (lane 2) compared to controls (lanes 1 and 3).
consistent with the cells exhibiting increased DNA syn- cdc2 was barely detected by immunostaining and
thesis in response to C5b-9. Western blot in VEC prior to exposure of Anti-Fx1A
and C5b-9 (results not shown). Immunostaining (Fig. 4)
M phase cell cycle proteins are altered by C5b-9 and protein levels (Fig. 4) were readily detected in con-
Mitosis and cytokinesis are regulated by the M phase trol VEC (groups 2 and 3) grown in Nuserum-containing
cell cycle proteins, cdc2 and its partner cyclin B [23]. media for 24 hours. In contrast, cdc2 immunostaining
Cyclin B protein was barely detected by immunostaining (Fig. 4) and protein levels by Western blot analysis (Fig.
or Western blot analysis in VEC prior to sensitization 3) were lower in C5b-9 attacked VEC (group 1) grown
with anti-Fx1A (results not shown). Cyclin B protein was in Nuserum for 24 hours compared to controls.
detected by immunostaining and Western blot analysis in These results show that the failure of VEC to undergo
control VEC grown in serum for 24 hours after exposure mitosis and cytokinesis following sublytic C5b-9 attack
to anti-Fx1A without C5b-9 (group 2) and control VEC was associated with decreased expression of the M phase
not exposed to anti-Fx1A (group 3) (Fig. 3). In contrast, cell cycle proteins, cyclin B and cdc2.
cyclin B was barely detected by immunostaining and
Western blot analysis (Fig. 3) in VEC grown in Nuserum
DISCUSSIONfor 24 hours after exposure to sublytic C5b-9 (group
In the current study we have shown that VEC in vitro1), and the levels were lower in C5b-9 attacked VEC
compared to controls. sensitized by incubation with low concentrations of anti-
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Fig. 4. Expression for cdc2. There was a decrease in immunostaining for cdc2 in VEC exposed to sublytic C5b-9 (group 1) (A) compared to
control (group 2) (B). The Western blot analysis for cdc2 demonstrates that cdc2 levels decreased in C5b-9 stimulated VEC (lane 2) compared
to control VEC that did (group 2, lane 3) or did not receive anti-VEC antibody (group 3, lane 1).
VEC IgG (anti-Fx1A) and then exposed to sublytic con- tial increase in cell number [8]. To better understand the
response of the VEC to sublytic C5b-9 and relate it tocentrations of fresh serum (C1) to activate complement
and induce formation of membrane-inserted C5b-9 com- proliferation and cell cycle control, the present study
was undertaken to examine the effects of sublytic C5b-9plexes, increase the expression of cyclin A and CDK2
and enter S phase in the presence of growth factors. on VEC proliferation in vitro where other variables can
be better controlled.However, C5b-9 decreases cyclin B and cdc2 expression,
resulting in the delay in G2/M progression. Earlier studies by our group [11] and others [31, 32,
36–38] have focused on the cytokines responsible forIn experimental membranous nephropathy induced by
antibody to the visceral glomerular epithelial cell (VEC) VEC proliferation. In the current study, VEC were
briefly (30 min) exposed to an antibody directed to anti-or podocyte, glomerular injury that occurs as a conse-
quence of C5b-9 attack on VEC results in cell activation gens on the VEC (anti-Fx1A) followed by sublytic con-
centrations of fresh, complement sufficient serum (C1)and production of oxidants and proteases that damage
underlying GBM [4, 33, 34]. Accompanying this process or control serum which lacked C6 (C2). The first finding
in this study was that the sublytic C5b-9 attack (in theis a low-grade increase in DNA synthesis, which is com-
plement-dependent [11]. However, there is no apparent absence of a source of growth factors) was not sufficient
by itself to increase DNA synthesis in vitro. However,increase in VEC number [11, 14]. This is in marked
contrast to the mesangial cell [35], which also makes prior sublytic injury to VEC by C5b-9 significantly aug-
mented entry into the S phase of the cell cycle (DNAoxidants and proteases in response to antibody/comple-
ment attack in vivo [33], but exhibits a dramatic prolifera- synthesis) induced by growth factors (Nuserum). In con-
trast, antibody binding to the VEC in the absence oftive response as well, mediated by PDGF, with a substan-
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C5b-9 (C2 serum) did not increase DNA synthesis com- The postulate that C5b-9 may have a direct effect on
pared to VEC grown in media containing Nuserum that DNA synthesis is consistent with what is known of the
had not been exposed to antibody. activation of cell signaling pathways by C5b-9, many of
The results of this study differ from findings in other which participate in receptor mediated processes includ-
cell types. C5b-9 alone (in the absence of other growth ing the response to growth factors. Thus, sublytic C5b-9
factors) is sufficient to increase DNA synthesis in certain can induce a transient increase in cytosolic calcium [40],
nonrenal cells, including 3T3 [39], B cells [40] and oligo- activation of protein kinase C [45], phospholipase A2
dendrocytes [41]. Thus, in contrast to these studies, we [46], PGI2 formation [47] and the MAPK pathway [48,
were unable to show that the sublytic C5b-9 attack by 49], and increased expression of certain transcription
itself was sufficient to induce DNA synthesis in the ab- factors [41] and nuclear factor-kB (NF-kB) [50].
sence of other mitogens. However, C5b-9 did increase In this study we explored the possibility that the effect
DNA synthesis in the presence of growth factors. These of C5b-9 on VEC proliferation occurs at the level of the
results are the first, to our knowledge, to establish that cell cycle. Studies of C5b-9-induced effects on cell cycle
sublytic C5b-9 can augment DNA synthesis in renal cells in VEC in vitro are of particular interest if they help to
in vitro. understand events that occur in vivo. In both human
To determine whether or not the sublytic C5b-9 effect and experimental membranous nephropathy the C5b-9
on DNA synthesis after exposure to serum was a direct attack on VEC is an established (experimental) or likely
or indirect one, we exposed normal VEC to supernatants (human) pathogenic mechanism, but mitotic arrest ap-
of C5b-9 stimulated VEC and found that these superna- parently occurs and no increase in VEC numbers is seen
tants contained mitogenic activity. However, the increase [14]. In other models of VEC injury, Rennke and Kritz
in DNA synthesis was only 50% of that induced by direct have proposed that the inability of the VEC to prolifer-
C5b-9 stimulation. This discrepancy could reflect a loss ate in vivo may underlie the development of progressive
of growth factors during culture or the transferring of glomerulosclerosis [14–17, 51]. In PHN, we have estab-
supernatants. However, the results are also consistent lished that some increase in DNA synthesis assessed by
with the possibility that C5b-9 has both a direct effect PCNA staining occurs, mitotic figures are seen and S
on proliferation independent of other mitogens as well phase cyclins and the CDK-inhibitors p21 and p27 are
as an indirect effect resulting from release of mitogens. increased [11, 52]. This increased expression of CKI may
The indirect effect is consistent with other studies that prevent progression through the S phase in vivo [52].
document the release of several potential mitogens from Our results in vitro are similar in some respects but differ
cells following C5b-9 attack, including reactive oxygen in others. In vitro, C5b-9 also induced an increase in
species, interleukin (IL)-1, IL-6 and tumor necrosis
BrdU staining (in the presence of Nuserum, a source of
factor-a (TNF-a) [3, 42, 43]. Because bFGF is a mito-
growth factors) and an increase in S phase cyclin andgenic growth factor for VEC in vitro [32] and bFGF has
CDK. However, the expression of the CKI’s p21 andbeen shown to be up-regulated following C5b-9 medi-
p27 was reduced rather than increased. Despite this,ated VEC injury in experimental membranous nephrop-
progression through M phase and cell division did notathy (PHN model) [12], we next examined if bFGF was
occur, apparently due to reduced expression of M phasethe mitogen released following C5b-9 induced VEC stim-
cyclins B and CDC2. Thus, the failure of VEC to prolifer-ulation in vitro. Our results show that neutralizing bFGF
ate in response to C5b-9 in vitro appears to reflect thewith a specific anti-bFGF antibody did not reduce C5b-9
effects on M phase cell cycle proteins rather than theinduced DNA synthesis. The concentration of anti-bFGF
effect of CKI. Another explanation may be that C5b-9antibody used reduced bFGF-stimulated DNA synthesis
delays G2/M phase progression. The mechanisms werein VEC. However, we did not measure the concentration
not determined in the current study.of bFGF in the supernatants. This indirect method used
The reasons for this discrepancy in CKI expression inin this study showing that bFGF did not mediate C5b-9
vivo and in vitro are not clear, but could reflect differ-induced DNA synthesis also differs from results reported
ences in the environment in which the VEC lives in vivoin nonrenal cells [44]. These studies suggest that the
versus in vitro, differences in cell-matrix attachments,mechanisms by which C5b-9 induces DNA synthesis may
differences in the amount of C5b-9 to which they arebe cell type specific. PDGF has been shown to mediate
exposed (there is likely more in vitro), and differencesC5b-9 induced mitogenesis in certain nonrenal cells [39].
in the timing required for the anti-Fx1A antibody to beAlthough we have previously shown an increase in
shed. Moreover, since M phase cyclins were not studiedPDGF synthesis by C5b-9 stimulated VEC [11], PDGF
in vivo, it is quite possible that a similar block in the Mis not a likely mitogen for these cells since VEC lack
phase occurs in this setting as well. In any event, togetherPDGF receptors [11]. Further studies are needed to bet-
these studies show that effects of C5b-9 on cell cycleter define the nature of the mitogen released by VEC
in response to C5b-9. regulatory proteins may in large part explain the failure
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PVG rats; C2, complement deficient PVG rats; CDK, cyclin dependentof VEC to divide and proliferate in response to antibody-
kinase; CKI, cyclin kinase inhibitors; GBM, gomerular basement mem-
complement mediated injury. brane; IL, interleukin; LDH, lactate dehydrogenase; NADH, nicotin-
An alternative explanation for our results would be amide adenine dinucleotide; p21, p21WAF1,CIP1; p27, p27Kip1; TGF-b, trans-
forming growth factor-b; TNF-a, tumor necrosis factor-alpha; VEC,that the cell number did not increase in response to
glomerular visceral epithelial cell.C5b-9 because cell death was increased. We believe this
is unlikely for two reasons. First, in pilot studies we
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